Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Glioma 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Medulloblastoma 7Lung Neoplasms 7Wilms Tumor 6Sarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Central Nervous System Neoplasms 6Rhabdomyosarcoma 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma, Ewing 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Stomach Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2

Interventions

Specimen Handling 3Biopsy 3X-Rays 2Magnetic Resonance Spectroscopy 2veliparib 1trastuzumab biosimilar HLX02 1pertuzumab 1irinotecan sucrosofate 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Ferrosoferric Oxide 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Malignant Solid Neoplasm × X-Rays × Clear all
NCT06360588 2026-04-17

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06136897 2026-04-13

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡